Oragenics Book Value 2011-2026 | OGEN

Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.

What is included in book value

Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.

Features of the metric

Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account.
Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market.
Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors.
Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.

Annual Book Value Oragenics

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
8.28 M	-212 K	4.97 M	14.8 M	28.2 M	18.7 M	17.2 M	20.9 M	6.32 M	2.97 M	4.73 M	10.3 M	15.8 M	9.23 M	-8.18 M

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
28.2 M	-8.18 M	10.3 M

Quarterly Book Value Oragenics

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
9.83 M	-2.13 M	138 K	-212 K	3.08 M	1.33 M	2.63 M	3.17 M	-	-	-	14.8 M	15 M	18.5 M	22.2 M	28.2 M	31.1 M	35.2 M	37.4 M	18.7 M	18.7 M	18.7 M	18.7 M	19.8 M	19.8 M	19.8 M	19.8 M	22 M	22 M	22 M	22 M	7.21 M	7.21 M	7.21 M	7.21 M	4.31 M	4.31 M	4.31 M	4.31 M	5.78 M	5.78 M	5.78 M	5.78 M	11.1 M	11.1 M	11.1 M	11.1 M	16.8 M	16.8 M	16.8 M	16.8 M	10.5 M	10.5 M	10.5 M	10.5 M	-8.18 M	-6.54 M	-5.03 M	1.27 M

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
37.4 M	-8.18 M	11.9 M

Book Value of other stocks in the Biotechnology industry

Issuer	Book Value	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	49 M	-	2.43 %	$ 254 M	Germany
ARCA biopharma ABIO	382 M	-	1052.0 %	$ 415 M	USA
Takeda Pharmaceutical Company Limited TAK	5.18 T	$ 18.06	-	$ 28.2 B	Japan
Amphastar Pharmaceuticals AMPH	789 M	$ 19.44	-0.46 %	$ 909 M	USA
Aeterna Zentaris AEZS	13.2 M	-	5.93 %	$ 314 M	Canada
AgeX Therapeutics AGE	-37 K	-	-10.17 %	$ 12.2 K	USA
Aeglea BioTherapeutics AGLE	715 M	-	-	$ 1.01 B	USA
AIkido Pharma AIKI	39.9 M	-	1.93 %	$ 17.4 M	USA
Akouos AKUS	234 M	-	0.23 %	$ 488 M	USA
Akero Therapeutics AKRO	750 M	-	-	$ 3.67 B	USA
I-Mab IMAB	5.63 B	-	-	$ 866 M	China
Alexion Pharmaceuticals, Inc. ALXN	253 M	-	-	$ 40.3 B	USA
Genfit SA GNFT	282 M	-	2.54 %	$ 160 B	France
Albireo Pharma ALBO	176 M	-	-0.23 %	$ 916 M	USA
Biophytis SA BPTS	34.9 M	-	-13.47 %	$ 169 M	France
Aileron Therapeutics ALRN	16.9 M	-	10.36 %	$ 9.8 M	USA
Aptinyx APTX	38.3 M	-	-39.0 %	$ 4.57 M	USA
Midatech Pharma plc MTP	8.32 M	-	-18.52 %	$ 27.3 M	Britain
EyeGate Pharmaceuticals, Inc. EYEG	2.33 B	-	-1.52 %	$ 24.7 M	USA
Arena Pharmaceuticals ARNA	785 M	-	-6.81 %	$ 3.04 B	USA
Applied Genetic Technologies Corporation AGTC	29.5 M	-	-	$ 26.5 M	USA
Avenue Therapeutics ATXI	1.86 M	-	-52.27 %	$ 4.45 M	USA
Ayala Pharmaceuticals AYLA	7.77 M	-	-	$ 7.46 M	Israel
Atreca BCEL	78.4 M	-	-11.76 %	$ 5.79 M	USA
Protara Therapeutics TARA	196 M	$ 5.03	-3.08 %	$ 215 M	USA
Acorda Therapeutics ACOR	109 M	-	-24.86 %	$ 820 K	USA
Tarsus Pharmaceuticals TARS	343 M	$ 67.0	-0.3 %	$ 2.8 B	USA
bluebird bio BLUE	195 M	-	-	$ 546 M	USA
Acasti Pharma ACST	66.6 M	-	4.01 %	$ 150 M	Canada
Институт стволовых клеток человека ISKJ	10.6 M	-	-	-	Russia
Theravance Biopharma TBPH	486 M	$ 14.9	-1.91 %	$ 750 M	Cayman-islands
Avid Bioservices CDMO	60.9 M	-	-	$ 789 M	USA
Adverum Biotechnologies ADVM	70.7 M	-	-	$ 86.2 M	USA
Acer Therapeutics ACER	-16.8 M	-	2.71 %	$ 14 M	USA
Advaxis ADXS	16.6 M	-	-9.65 %	$ 45.9 M	USA
Autolus Therapeutics plc AUTL	427 M	$ 1.2	-6.97 %	$ 306 M	Britain
BeiGene, Ltd. BGNE	4.36 B	-	0.49 %	$ 251 B	Cayman-islands
Bio-Techne Corporation TECH	2.56 B	$ 51.31	-2.65 %	$ 8.08 B	USA
Tenax Therapeutics TENX	97.1 M	$ 14.64	-2.2 %	$ 574 M	USA
BioDelivery Sciences International BDSI	188 M	-	-4.8 %	$ 255 M	USA
Cara Therapeutics CARA	57.1 M	-	-3.03 %	$ 260 M	USA
ChemoCentryx CCXI	286 M	-	-	$ 3.74 B	USA
Enlivex Therapeutics Ltd. ENLV	23.6 M	$ 1.07	-2.29 %	$ 21.9 M	Israel
Teva Pharmaceutical Industries Limited TEVA	7.91 B	$ 28.76	-3.43 %	$ 32.9 B	Israel
Enochian Biosciences ENOB	-21.3 M	-	-	$ 40.5 M	USA
CureVac N.V. CVAC	688 M	-	-	$ 867 M	Germany
Equillium EQ	28.6 M	$ 2.03	-1.46 %	$ 116 M	USA
Eton Pharmaceuticals ETON	26.2 M	$ 23.81	1.51 %	$ 641 M	USA
Bellerophon Therapeutics BLPH	2.53 M	-	-74.18 %	$ 955 K	USA
CRISPR Therapeutics AG CRSP	1.92 B	$ 46.38	-2.45 %	$ 4.17 B	Schweiz